Showing 8011-8020 of 8879 results for "".
- Industry Responds to COVID-19: Allergan Foundation Doubles Down on COVID-19 Donationshttps://practicaldermatology.com/news/industry-responds-allergan-foundation-doubles-down-on-covid-19-donations/2460385/The Allergan Foundation fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic, doubling their COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organ
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy o
- Supportive Oncodermatology Interventions Improve Patient Quality of Lifehttps://practicaldermatology.com/news/supportive-oncodermatology-interventions-improve-patient-quality-of-life-1/2460377/Enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score, according to a recent survey from the George Washington University (GW) Cancer Center. The
- FDA Approves Galderma's Restylane Kysse for Lip Augmentation and Upper Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-kysse-for-lip-augmentation-and-upper-perioral-rhytids-1/2460374/The FDA has approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OB
- Cutera's TruSculpt Flex Wins 2020 Good Housekeeping Awardhttps://practicaldermatology.com/news/cuteras-trusculpt-flex-wins-2020-good-housekeeping-award/2460373/Congrats! Cutera’s truSculpt flex won a Good Housekeeping 2020 Beauty Award Winner for Ultimate Body Product. truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen. It is also cleared for th
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/
- San Diego Dermatology Symposium Reschedules to Septemberhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-reschedules-to-september/2460350/San Diego Dermatology Symposium will be held September 11-13, 2020, a shift from its original date. "The safety of our attendees, faculty, and exhibitors is our utmost priority, and we have been closely monitoring guidance from federal, state and local governments, as well as the World Healt